Tag: Oladimeji Ewumi

  • ‘Why I am passionate about medical writing’

    ‘Why I am passionate about medical writing’

    A medical writer in the life science industry, Oladimeji Ewumi has revealed why he is passionate about translating complex science into clear, accessible communication. Speaking in an interview, Ewumi said the writing industry is a multi-billion-dollar field with vast opportunities spread across several niches.

    ‘I had my first stint with writing during my undergraduate program as a research assistant under the supervision of an associate professor at the Faculty of Clinical Sciences, but I never really considered it a viable career option. My RA role entailed writing, editing, and supporting research as well as gathering multiple research papers in the areas of fetal and maternal health.

    Upon graduation, I was drawn to data science and artificial intelligence due to recommendations from a friend and the buzz surrounding AI job roles at that time. However, during the COVID-19 pandemic, I came across a free 1-week writing boot camp featuring professional writers from various industries worldwide, which intensified my passion.

    During the training, I learned that the writing industry is a multi-billion-dollar field with vast opportunities spread across several niches.

    It was exciting to know that within a single niche, there are several types of deliverables in demand. You could also work remotely as an independent contractor or communications specialist from anywhere in the world. I was able to niche down to healthcare and AI due to my passion and prior experience. I enrolled in a second bootcamp with The Writer’s Den that equipped me with all the necessary tools and information I needed to set up a scalable freelance writing business.Starting in the last quarter of 2020, I began guest-posting thought leadership articles on AI in the healthcare and life sciences as well as core health articles. I secured my first major client just seven months later, and the rest is history. He disclosed.

    On how he anticipates the medical writing landscape evolving in the next five to 10 years,   Ewumi said “over the next five to 10 years, the medical writing landscape is likely to become even more dynamic due to the emergence of new technologies. As a result, entry-level roles may become nonexistent, and mid-level roles will face higher entry barriers. As regulatory requirements evolve and new therapies emerge, writers will need to be adaptable, digitally fluent, and comfortable working with diverse teams across multiple time zones.

    “Let me state that great medical writing will continue to depend on something no algorithm can replace—the human touch. While the influx of technology is undeniable, these are exciting times for medical writers.”

    Ewumi’s most extensive projects are in the areas of endocrinology, nephrology, and cardiology. Others are primary care, oncology, public health, psychiatry, dermatology, neurology, gastroenterology, ophthalmology, pediatrics, gene editing, and surgery. However, he finds every therapeutic area he has worked on exciting and fulfilling.

    Read Also: Bridging Nigeria’s Healthcare Divide: Linking Informal Healthcare Providers to the Formal Health System

    He avoids restricting himself to a particular therapeutic area because the fun in medical writing is in the diversity. “Just like the proverbial “thief in the night,” you usually never know what area of specialty your next project will be, and again, some projects stretch across multiple therapeutic areas. For example, I wrote a coverage article on the American Heart Association’s metabolic syndrome initiative to educate physicians on its potential impact and discuss strategies for integrating new ideas into kidney care. While this syndrome affects the heart and kidneys, two distinct organs, it has an endocrine undertone.

    “Because this was an interview-heavy piece that required me to interview the initiative lead, an associate professor of cardiology at Johns Hopkins, and two other associate professors of nephrology from Harvard and the University of Cincinnati, I had to read extensively on these therapeutic areas. As a medical writer, you may never have a favorite therapeutic area due to the multidisciplinary nature of some topics,” He revealed.

    To ensure scientific accuracy, Ewumi, relies on credible and up-to-date primary sources, including PubMed, Frontiers, the CDC, NIH, and leading journals such as JAMA. “I prioritize studies published within the last five years and summarize findings clearly and objectively to reflect what the evidence truly shows. Another effective way to achieve scientific accuracy is to obtain expert insight and perspectives from a specialist physician in the therapeutic area I’m working on through interviews. The need for this varies by publication and has led to interviews with medical faculty from Harvard, the University of Illinois at Chicago, New York University Langone Health, Yale, RUSH, Baylor, the University of Pennsylvania, and Columbia University, to name a few.’ He stated.”

  • Oladimeji Ewumi calls for action on personalized cancer care at EU Forum

    Oladimeji Ewumi calls for action on personalized cancer care at EU Forum

    A Nigerian healthcare, life sciences, and medical AI writer, Oladimeji Ewumi took center stage at the European Alliance for Personalized Medicine (EAPM) seminar that examined how personalized medicine can improve cancer diagnosis and treatment across regions, particularly in Africa.

    The virtual seminar, titled: “Determining a Path for Optimal Integration of Access & Diagnostics for All & Public Health Genomics,” was held on May 24, 2022, and brought together policymakers, researchers, clinicians, and patient advocates from Europe and Africa.

    Hosted by EAPM in Brussels, the event focused on the opportunities and challenges of integrating personalized medicine into health systems, building on a 2021 index that evaluates access to diagnostics and genomics. 

    The organization has long advocated for regulatory reform across the European Union to enable earlier patient access to personalized therapies and to strengthen research and innovation.

    Speaking alongside leaders such as Cancer Alliance CEO Salome Meyer, Prof. Collet Dandara of the University of Cape Town, and experts from the South African Medical Research Council, KEMRI-Wellcome Trust, and ICGEB, Ewumi brought an African-centered perspective to the discussion. 

    His contribution focused on the structural and policy barriers limiting equitable cancer care across the continent, including late diagnosis, limited access, weak research infrastructure, and challenges in conducting well-powered oncology clinical trials.

    Drawing from his presentation, Ewumi emphasized that Africa faces a disproportionate cancer burden, with approximately one million new cases annually and projections of a 70% increase by 2030. 

    Late-stage diagnosis remains common, contributing to poor outcomes, compounded by shortages of oncologists, limited diagnostic facilities, and high treatment costs. He argued that these challenges demand a shift away from “one-size-fits-all” approaches toward personalized, molecularly guided care tailored to African populations.

    Ewumi outlined a practical framework for action, highlighting the roles of governance, clinical standardization, and demand-side awareness, alongside equitable reimbursement, testing infrastructure, and evidence generation on the supply side. 

    He pointed to opportunities for governments to leverage Africa’s expanding telecommunications sector to improve cancer awareness and patient education, while calling for investment in diagnostic infrastructure and genomics research to support precision oncology.

    Ewumi also emphasized the importance of strengthening diagnostic and research infrastructure as a foundation for equitable cancer care. 

    He called for the establishment of testing and treatment facilities across local governments, alongside investment in modern diagnostic equipment and workforce training to enable timely screening, diagnosis, and treatment.

    Emphasizing that evidence generation is critical, he noted that limited recruitment of African populations into clinical trials has left key gaps in understanding cancer biology on the continent. 

    Addressing these gaps, he argued, would allow the development of population-specific treatment protocols and support the earlier use of personalized therapies —matching the right patient with the proper treatment from the outset to improve outcomes and quality of life.

    The panel discussion ultimately led to the publication of the research paper “Fighting Cancer around the World: A Framework for Action,” released in October 2022, which captured the policy insights and recommendations emerging from the forum. 

    In his closing remarks, Ewumi underscored the urgency of translating discussion into action, stating, “The time is right to implement personalized molecular medicine for all patients with cancer in Africa and the world.”

    By bridging policy, research, and real-world health system challenges, Ewumi’s contribution reinforced the growing consensus that personalized medicine is no longer aspirational but essential for improving cancer outcomes globally.